|
Gene: TBL1XR1 |
Gene summary for TBL1XR1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TBL1XR1 | Gene ID | 79718 |
Gene name | TBL1X receptor 1 | |
Gene Alias | C21 | |
Cytomap | 3q26.32 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9BZK7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79718 | TBL1XR1 | GSM4909281 | Human | Breast | IDC | 6.88e-17 | 5.09e-01 | 0.21 |
79718 | TBL1XR1 | GSM4909285 | Human | Breast | IDC | 1.10e-10 | 3.83e-01 | 0.21 |
79718 | TBL1XR1 | GSM4909293 | Human | Breast | IDC | 1.62e-32 | 6.35e-01 | 0.1581 |
79718 | TBL1XR1 | GSM4909298 | Human | Breast | IDC | 1.55e-07 | 2.75e-01 | 0.1551 |
79718 | TBL1XR1 | GSM4909303 | Human | Breast | IDC | 1.44e-03 | 5.13e-01 | 0.0438 |
79718 | TBL1XR1 | GSM4909304 | Human | Breast | IDC | 3.78e-17 | 5.19e-01 | 0.1636 |
79718 | TBL1XR1 | GSM4909308 | Human | Breast | IDC | 6.49e-07 | 3.78e-01 | 0.158 |
79718 | TBL1XR1 | GSM4909311 | Human | Breast | IDC | 1.80e-11 | -1.44e-01 | 0.1534 |
79718 | TBL1XR1 | GSM4909312 | Human | Breast | IDC | 5.16e-03 | 6.20e-02 | 0.1552 |
79718 | TBL1XR1 | GSM4909319 | Human | Breast | IDC | 5.82e-11 | -2.69e-01 | 0.1563 |
79718 | TBL1XR1 | GSM4909320 | Human | Breast | IDC | 1.36e-02 | -2.95e-01 | 0.1575 |
79718 | TBL1XR1 | GSM4909321 | Human | Breast | IDC | 5.60e-04 | -1.35e-01 | 0.1559 |
79718 | TBL1XR1 | brca1 | Human | Breast | Precancer | 3.08e-02 | -2.29e-01 | -0.0338 |
79718 | TBL1XR1 | M2 | Human | Breast | IDC | 1.72e-02 | 3.11e-01 | 0.21 |
79718 | TBL1XR1 | NCCBC14 | Human | Breast | DCIS | 8.23e-08 | 2.51e-01 | 0.2021 |
79718 | TBL1XR1 | NCCBC5 | Human | Breast | DCIS | 6.64e-04 | -6.48e-03 | 0.2046 |
79718 | TBL1XR1 | P1 | Human | Breast | IDC | 6.74e-09 | 3.04e-02 | 0.1527 |
79718 | TBL1XR1 | P2 | Human | Breast | IDC | 5.17e-04 | 4.08e-01 | 0.21 |
79718 | TBL1XR1 | P3 | Human | Breast | IDC | 2.50e-02 | 5.66e-01 | 0.1542 |
79718 | TBL1XR1 | DCIS2 | Human | Breast | DCIS | 1.11e-35 | 1.34e-01 | 0.0085 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006082812 | Lung | AIS | regulation of canonical Wnt signaling pathway | 52/1849 | 253/18723 | 2.40e-07 | 2.22e-05 | 52 |
GO:006007012 | Lung | AIS | canonical Wnt signaling pathway | 59/1849 | 303/18723 | 2.73e-07 | 2.37e-05 | 59 |
GO:003017712 | Lung | AIS | positive regulation of Wnt signaling pathway | 29/1849 | 140/18723 | 9.01e-05 | 2.21e-03 | 29 |
GO:000647611 | Lung | AIS | protein deacetylation | 23/1849 | 101/18723 | 1.06e-04 | 2.54e-03 | 23 |
GO:00165751 | Lung | AIS | histone deacetylation | 19/1849 | 82/18723 | 3.23e-04 | 5.84e-03 | 19 |
GO:003560111 | Lung | AIS | protein deacylation | 23/1849 | 112/18723 | 5.25e-04 | 8.42e-03 | 23 |
GO:009026312 | Lung | AIS | positive regulation of canonical Wnt signaling pathway | 22/1849 | 106/18723 | 5.91e-04 | 9.03e-03 | 22 |
GO:00987321 | Lung | AIS | macromolecule deacylation | 23/1849 | 116/18723 | 8.77e-04 | 1.19e-02 | 23 |
GO:001605522 | Lung | AAH | Wnt signaling pathway | 28/613 | 444/18723 | 7.63e-04 | 2.63e-02 | 28 |
GO:019873822 | Lung | AAH | cell-cell signaling by wnt | 28/613 | 446/18723 | 8.18e-04 | 2.75e-02 | 28 |
GO:003011122 | Lung | MIAC | regulation of Wnt signaling pathway | 41/967 | 328/18723 | 1.51e-07 | 3.69e-05 | 41 |
GO:001605531 | Lung | MIAC | Wnt signaling pathway | 50/967 | 444/18723 | 1.88e-07 | 4.02e-05 | 50 |
GO:019873831 | Lung | MIAC | cell-cell signaling by wnt | 50/967 | 446/18723 | 2.16e-07 | 4.11e-05 | 50 |
GO:001657022 | Lung | MIAC | histone modification | 45/967 | 463/18723 | 3.58e-05 | 1.97e-03 | 45 |
GO:006082822 | Lung | MIAC | regulation of canonical Wnt signaling pathway | 28/967 | 253/18723 | 1.23e-04 | 5.10e-03 | 28 |
GO:006007022 | Lung | MIAC | canonical Wnt signaling pathway | 31/967 | 303/18723 | 2.31e-04 | 7.86e-03 | 31 |
GO:004316123 | Lung | MIAC | proteasome-mediated ubiquitin-dependent protein catabolic process | 37/967 | 412/18723 | 7.87e-04 | 1.76e-02 | 37 |
GO:003017722 | Lung | MIAC | positive regulation of Wnt signaling pathway | 17/967 | 140/18723 | 9.02e-04 | 1.92e-02 | 17 |
GO:001049823 | Lung | MIAC | proteasomal protein catabolic process | 40/967 | 490/18723 | 2.92e-03 | 3.99e-02 | 40 |
GO:009026322 | Lung | MIAC | positive regulation of canonical Wnt signaling pathway | 13/967 | 106/18723 | 3.18e-03 | 4.23e-02 | 13 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0431012 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa04310 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
hsa043101 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
hsa043102 | Colorectum | MSS | Wnt signaling pathway | 53/1875 | 171/8465 | 4.24e-03 | 1.86e-02 | 1.14e-02 | 53 |
hsa043103 | Colorectum | MSS | Wnt signaling pathway | 53/1875 | 171/8465 | 4.24e-03 | 1.86e-02 | 1.14e-02 | 53 |
hsa043104 | Colorectum | FAP | Wnt signaling pathway | 46/1404 | 171/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 46 |
hsa043105 | Colorectum | FAP | Wnt signaling pathway | 46/1404 | 171/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 46 |
hsa0431010 | Endometrium | AEH | Wnt signaling pathway | 37/1197 | 171/8465 | 4.68e-03 | 2.53e-02 | 1.86e-02 | 37 |
hsa0431013 | Endometrium | AEH | Wnt signaling pathway | 37/1197 | 171/8465 | 4.68e-03 | 2.53e-02 | 1.86e-02 | 37 |
hsa0431022 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa0431032 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa043108 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
hsa0431011 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
hsa0431021 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
hsa0431031 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
hsa0431041 | Lung | MIAC | Wnt signaling pathway | 21/507 | 171/8465 | 1.30e-03 | 1.40e-02 | 1.01e-02 | 21 |
hsa0431051 | Lung | MIAC | Wnt signaling pathway | 21/507 | 171/8465 | 1.30e-03 | 1.40e-02 | 1.01e-02 | 21 |
hsa0431016 | Oral cavity | EOLP | Wnt signaling pathway | 37/1218 | 171/8465 | 6.23e-03 | 1.83e-02 | 1.08e-02 | 37 |
hsa0431017 | Oral cavity | EOLP | Wnt signaling pathway | 37/1218 | 171/8465 | 6.23e-03 | 1.83e-02 | 1.08e-02 | 37 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TBL1XR1 | SNV | Missense_Mutation | c.1145N>G | p.Asn382Ser | p.N382S | Q9BZK7 | protein_coding | tolerated(0.66) | benign(0.001) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
TBL1XR1 | SNV | Missense_Mutation | c.1454N>A | p.Gly485Glu | p.G485E | Q9BZK7 | protein_coding | deleterious(0.02) | benign(0.275) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
TBL1XR1 | SNV | Missense_Mutation | c.1256N>T | p.Ser419Phe | p.S419F | Q9BZK7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
TBL1XR1 | SNV | Missense_Mutation | rs372813783 | c.346G>T | p.Ala116Ser | p.A116S | Q9BZK7 | protein_coding | tolerated(0.67) | benign(0) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
TBL1XR1 | SNV | Missense_Mutation | c.854N>T | p.Gly285Val | p.G285V | Q9BZK7 | protein_coding | deleterious(0.04) | probably_damaging(0.992) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TBL1XR1 | insertion | Frame_Shift_Ins | novel | c.423_424insTA | p.Ala142Ter | p.A142* | Q9BZK7 | protein_coding | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
TBL1XR1 | insertion | Frame_Shift_Ins | novel | c.423_424insTA | p.Ala142Ter | p.A142* | Q9BZK7 | protein_coding | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TBL1XR1 | insertion | Frame_Shift_Ins | novel | c.423_424insTA | p.Ala142Ter | p.A142* | Q9BZK7 | protein_coding | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
TBL1XR1 | SNV | Missense_Mutation | novel | c.65N>T | p.Ser22Phe | p.S22F | Q9BZK7 | protein_coding | tolerated(0.09) | benign(0.014) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TBL1XR1 | SNV | Missense_Mutation | novel | c.241N>G | p.Leu81Val | p.L81V | Q9BZK7 | protein_coding | deleterious(0.01) | probably_damaging(0.912) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
79718 | TBL1XR1 | TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE | allopurinol | ALLOPURINOL | 30924126 |
Page: 1 |